iCM 012
Alternative Names: iCM-012; TUM-012; TUM012 - iCoat MedicalLatest Information Update: 18 Jun 2024
At a glance
- Originator iCoat Medical
- Class Ischaemic heart disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Renal transplant rejection
- Preclinical Cardiovascular disorders; Heart transplant rejection
- Research Liver transplant rejection
Most Recent Events
- 14 May 2024 iCoat Medical completes a phase I/II trial in Renal transplant rejection in Sweden (unspecified route, Infusion) (NCT05246618)
- 15 Nov 2023 iCoat Medical expects IND approval for pivotal study in H1 of 2024 (iCoat Medical pipeline, December 2024)
- 14 Mar 2023 iCoat Medical plans a phase II EMPIRE pilot trial for Renal transplant rejection in the fourth quarter of 2023 (iCoat Medical pipeline, March 2023)